TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05745584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics
Description: Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
Study: NCT01525368

Intervention type: BEHAVIORAL
Intervention: cognitive intervention
Description: Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
Study: NCT02690688

Intervention type: DEVICE
Intervention: determination of dynamic preload variables

Intervention type: DEVICE
Intervention: determination of dynamic preload variables
Study: NCT03420508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
Study: NCT03623802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Movement Therapy
Description: Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integral Movement Therapy
Description: Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
Study: NCT00598832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene lotion 0.1%
Description: Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene Lotion Vehicle
Description: Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
Study: NCT01900704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 750 ng
Description: SER120 750 ng

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120 1500 ng
Description: SER120 1500 ng

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01414010

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Trametes versicolor extract
Description: 1,200 mg, 3 times daily on an empty stomach for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: 250 mg, 3 times daily on an empty stomach for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 250 mg 3 times daily at least 1 hour before meals for 7 days
Study: NCT04134013

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination: Nutrition AND Chiropractic Adjustment
Description: LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
Study: NCT03420508

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ALKATI by Customized Nanostring Assay
Description: a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
Study: NCT04134013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic Adjustment: Spinal Manipulation Therapy
Description: LBP chiropractic adjustment per protocol
Study: NCT01700777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: 90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HABIT-ILE
Description: 90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards).
Study: NCT02835404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic External Radiotherapy
Description: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic External Radiotherapy
Description: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 252-Cf Neutron Intracavitary Brachytherapy
Description: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 252-Cf Neutron Intracavitary Brachytherapy
Description: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
Study: NCT05509647

Intervention type: DRUG
Intervention: Unfractionated heparin
Description: Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml

Intervention type: DRUG
Intervention: Unfractionated heparin
Description: Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
Study: NCT03863379

Intervention type: DIAGNOSTIC_TEST
Intervention: whole body DXA
Description: Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
Study: NCT02947997

Intervention type: DEVICE
Intervention: OFDI capsule
Description: Imaging of esophagus using OFDI capsule and system
Study: NCT02148198

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
Study: NCT01231334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone plus Adapalene
Description: Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin/benzoyl peroxide plus Adapalene
Description: Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
Study: NCT01260688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study: NCT02966288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: 3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral NSAID
Description: 800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
Study: NCT03938103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Go NAPSACC
Description: In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Go NAPSACC
Description: In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
Study: NCT00351767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Topically applied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbermin
Description: Topically applied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbermin
Description: Topically applied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbermin
Description: Topically applied
Study: NCT03389412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conditional alarm
Description: Eight weeks of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conditional alarm
Description: Eight weeks of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conditional alarm
Description: Eight weeks of treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conditional alarm
Description: Eight weeks of treatment.
Study: NCT04081402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HU-014
Description: Hutox Inj(Clostridium botulinum type A)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox Inj
Description: Botox Inj(Clostridium botulinum type A)
Study: NCT01835288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02148198

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
Study: NCT02158195

Intervention type: BIOLOGICAL
Intervention: blood samples

Intervention type: BIOLOGICAL
Intervention: blood samples
Study: NCT01944254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac output measurement at random to respiration
Description: Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac output measurement synchronised at start of expiration
Description: Cardiac output measurement obtained by PAC TD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac output measurement timed to instructed exhalation
Description: Cardiac output measurement obtained by PAC TD
Study: NCT02148198

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
Study: NCT00676091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-Valent Pneumococcal Conjugate Vaccine (7vPnc)
Study: NCT04646733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Diet Group
Description: The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No High Protein Diet Group
Description: No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
Study: NCT01767350

Intervention type: PROCEDURE
Intervention: Blood withdrawal for DNA
Description: Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up.
Study: NCT02213146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone human insulin
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone human insulin
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone human insulin
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huminsulin® Normal
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huminsulin® Normal
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huminsulin® Normal
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog®
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study: NCT01880879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: helios stent
Description: the group with helios stent implanted
Study: NCT02213146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study: NCT02071043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
Study: NCT02824315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
Study: NCT02071043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
Study: NCT03293914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign
Description: Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
Study: NCT00589875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN-2409
Description: Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
Study: NCT01736475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Description: Pharmacokinetic (PK) evaluation of ADVATE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Pharmacokinetic (PK) evaluation of BAX 855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Prophylaxis treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: On-demand treatment
Study: NCT02408887

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy (TT)
Description: Total removal of thyroid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy (TT)
Description: Total removal of thyroid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic central neck lymph node dissection (pCND)
Description: Lymph node dissection
Study: NCT00579462

Intervention type: OTHER
Intervention: Blood and Tissue studies
Description: Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
Study: NCT03881644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imigran
Description: All patients will undergo this intervention on one of two study days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: All patients will undergo this intervention on one of two study days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pituitary adenylate cyclase-activating peptide-38
Description: All patients will undergo this intervention on both study days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pituitary adenylate cyclase-activating peptide-38
Description: All patients will undergo this intervention on both study days